Craig L Slingluff Selected Research

Craig L Slingluff Research Topics

Disease

122	Melanoma (Melanoma, Malignant) 03/2024 - 01/2002
90	Neoplasms (Cancer) 04/2024 - 01/2002
24	Neoplasm Metastasis (Metastasis) 01/2023 - 08/2004
10	Tetanus 01/2022 - 11/2003
8	Testicular Neoplasms (Testicular Cancer) 01/2021 - 01/2004
7	Tertiary Lymphoid Structures 01/2023 - 01/2018
5	Pancreatic Neoplasms (Pancreatic Cancer) 03/2024 - 01/2016
4	Injection Site Reaction 01/2022 - 09/2004
4	Breast Neoplasms (Breast Cancer) 01/2020 - 10/2005
3	Lymphatic Metastasis 01/2023 - 03/2016
3	Ovarian Neoplasms (Ovarian Cancer) 11/2021 - 05/2008
3	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 02/2004
2	Adenocarcinoma 12/2023 - 01/2018
2	Anemia 01/2022 - 09/2004
2	Exanthema (Rash) 01/2022 - 01/2021
2	Fatigue 01/2022 - 05/2008
1	Pruritus (Itching) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Fever (Fevers) 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2022

Drug/Important Bio-Agent (IBA)

58	VaccinesIBA 03/2024 - 01/2002
54	Peptides (Polypeptides)IBA 03/2024 - 01/2002
29	AntigensIBA 04/2024 - 01/2004
19	Protein Subunit VaccinesIBA 01/2022 - 09/2004
18	Proteins (Proteins, Gene)FDA Link 03/2024 - 03/2003
15	incomplete Freund's adjuvantIBA 01/2022 - 11/2009
12	Cancer VaccinesIBA 04/2024 - 04/2005
10	CytokinesIBA 01/2020 - 01/2002
9	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022 - 11/2003
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 11/2005
8	AntibodiesIBA 08/2021 - 01/2002
8	EpitopesIBA 11/2014 - 03/2003
7	LigandsIBA 01/2023 - 08/2011
7	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2016
7	Interleukin-2 (IL2)IBA 12/2011 - 09/2004
6	InterferonsIBA 01/2023 - 01/2002
6	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2002
6	Monatide (IMS 3015)IBA 01/2022 - 11/2003
5	IpilimumabIBA 01/2021 - 01/2016
5	Toll-Like Receptor AgonistsIBA 01/2021 - 09/2011
5	Monophenol Monooxygenase (Tyrosinase)IBA 01/2021 - 11/2003
5	ChemokinesIBA 10/2016 - 11/2010
5	HLA-A2 Antigen (HLA A2 Antigen)IBA 05/2008 - 11/2003
4	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 03/2024 - 05/2008
4	Imiquimod (Aldara)FDA LinkGeneric 01/2023 - 01/2010
4	NivolumabIBA 10/2020 - 01/2016
4	HLA-A3 Antigen (HLA A3 Antigen)IBA 05/2008 - 11/2003
4	HLA Antigens (Human Leukocyte Antigens)IBA 05/2008 - 11/2004
3	pembrolizumabIBA 12/2023 - 12/2022
3	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2002
3	EmulsionsIBA 01/2022 - 11/2003
3	PhosphopeptidesIBA 11/2021 - 12/2014
3	poly ICLCIBA 01/2021 - 11/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2019 - 06/2008
3	Phosphotransferases (Kinase)IBA 01/2015 - 10/2005
3	Bevacizumab (Avastin)FDA Link 09/2013 - 06/2008
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2011 - 06/2008
2	Complementary DNA (cDNA)IBA 03/2024 - 03/2003
2	Immunoconjugates (Immunoconjugate)IBA 03/2024 - 02/2018
2	Toll-Like Receptor 7IBA 01/2023 - 01/2021
2	Colloids (Colloid)IBA 01/2023 - 11/2002
2	SulfurIBA 01/2023 - 11/2002
2	CateninsIBA 08/2021 - 07/2019
2	IntegrinsIBA 01/2021 - 02/2014
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 09/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 07/2011
2	CollagenIBA 01/2021 - 08/2004
2	ParaffinIBA 10/2020 - 09/2014
2	Filaggrin ProteinsIBA 10/2019 - 01/2016
2	EnzymesIBA 01/2019 - 08/2016
2	Monoclonal AntibodiesIBA 02/2018 - 04/2005
2	Interferon-gamma (Interferon, gamma)IBA 10/2016 - 09/2015
2	Proto-Oncogene Proteins B-rafIBA 08/2016 - 10/2005
2	PLX 4720IBA 08/2016 - 01/2015
2	Chemokine ReceptorsIBA 03/2016 - 11/2013
2	Melanoma-Specific AntigensIBA 09/2015 - 04/2006
2	Mitogen-Activated Protein KinasesIBA 01/2015 - 08/2004
2	tyrosine receptor (receptor, tyrosine)IBA 01/2015 - 08/2011
2	temsirolimus FDA Link 09/2013 - 07/2013
2	Protein Kinases (Protein Kinase)IBA 07/2013 - 10/2005
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2011 - 06/2008
2	Small Interfering RNA (siRNA)IBA 12/2011 - 06/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2011 - 08/2011
2	Sirolimus (Rapamycin)FDA Link 06/2008 - 10/2005
2	gp100(280-288) melanoma antigen peptideIBA 11/2004 - 11/2004
1	Chimeric Antigen ReceptorsIBA 03/2024
1	NF-kappa B (NF-kB)IBA 09/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023
1	Carcinoembryonic AntigenIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Liposomes (Liposome)IBA 01/2022

Therapy/Procedure

49	Therapeutics 03/2024 - 09/2004
29	Immunotherapy 12/2023 - 01/2002
7	Lymph Node Excision (Lymph Node Dissection) 01/2023 - 11/2002
3	Neoadjuvant Therapy 12/2023 - 01/2023
3	Biological Therapy 05/2011 - 12/2008
2	Gamma Cameras (Gamma Camera) 01/2023 - 04/2011
2	Metastasectomy 01/2021 - 01/2021
2	Immunomodulation 01/2018 - 05/2008
1	Drug Therapy (Chemotherapy) 01/2022